307 Westlake Avenue North
About Juno Therapeutics
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.
The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. Our goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.
August 5, 2013
Founders: : Hans Bishop, Richard Klausner, and Robert Nelsen
CEO and Co-founder: Hans Bishop
Please click here for job opportunities.
Please click here for clinical trial information.
Tweets by Juno
228 articles with Juno Therapeutics
Already-Rich Juno Therapeutics Reels In Another $134 Million, Has Raised $300 Million In Less Than 12 Months
Juno Therapeutics Appoints Biotech Investment Banking Leader Steve Harr As CFO And Head Of Corporate Development
Cellectis, Servier Forge Leukemia, Solid Tumors Pact To Battle With Novartis AG And Newbie Juno Therapeutics